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PALIFERMIN USE IN ADOLESCENT STEM CELL TRANSPLANT PATIENTS:
CASE REPORTS
Williams, D.1, Deoras, R.1, Seaton, A.2, Makonnen, T.3 1Children’s
National Medical Center, Washington, DC; 2University of Maryland;
3Virginia Commonwealth University
Purpose: This is a case series report of two adolescent stem cell
transplant patients who received palifermin therapy to decrease the
duration and severity of oral mucositis.
Background: Oral mucositis, an injury of the oral mucosa found
most comonly in patients receiving chemotherapy and/or radiation,
is one of the most debilitating toxicities associated with stem cell
transplantation. Oral mucositis has been associated with the need
for total parenteral nutrition, longer hospital admissions with an in-
crease in hospital charges, and an increased risk of mortality within
the first 100 days post-transplant.
Several risk factors have been identified for increased risk of severe
oral mucositis. Risk factors that may predispose patients to more se-
vere oral mucositis include alkylator agent chemotherapy stem cell
preparative regimens, radiation containing preparative regimens,
and herpes simplex virus.
Palifermin (Kepivance), a human keratinocyte growth factor, has
been used to decrease the incidence and severity of oral mucositis.
Palifermin is not FDA-approved for pediatric patients and reports
on its use in the pediatric hematopoietic stem cell transplant patient
population are limited.
This is a report of two cases of palifermin use in adolescent stemTable. Palifermin Results
Patient
Duration of
Mucositis (Days)
Most Severe WHO
Grade Oral Mucositis**
Able to Take Oral
Solids During Mucositis (Days) BMT Prep Regimen Transplant Type
1 4 2 4/4 BEAM, Radiation Augologous
2 11 1* 8/11 Fludarabine, Cyclophoshpamide, Total Body
Irradiation, Focal Mandible Radiation
Cord Blood
*Throat Pain, Abdominal Pain, No Oral Ulceration.
**World Health Oraganization.cell transplant patients. The observed patients include a 14 year-old
who received a double cord blood allogeneic transplant following
a fludarabine, cyclophosphamide total body irradiation and focal ra-
diation prep, and a 14 year-oldwho received an autologous transplant
following a BEAM (Carmustine, Etoposide, Cytarabine, Melphalan)
and focal radiation prep. In both cases, the use of palifermin pre-
vented progression to severe, grade three or four mucositis.
Results:
Conclusion: Palifermin is an effective alternative to decrease sever-
ity of oral mucositis in adolescent stem cell transplant patients.
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PHARMACISTS’ ROLE IN IMPLEMENTATION OF AN ALLOGENEIC HPC
TRANSPLANT PROGRAM
Lee, K.J., Wong-Yu, F.H., Chow, V. USC Norris Comprehensive Cancer
Center, Los Angeles, CA
The autologous hematopoietic progenitor cell (HPC) transplant
program at USC Norris Comprehensive Cancer Center has been in
practice since 1987. In 2011, the planning and implementation of al-
logeneic HPC transplant program began with efforts of a multi-dis-
ciplinary team of experts providing collaborative clinical practice.
Pharmacists played a key role especially in the creation of policies,
preprinted orders, drug therapy management, and education.
Pharmacists reviewed medications for the conditioning regimen,
graft-versus-host disease (GVHD) prophylaxis, and various support-
ive cares by evaluating literature and bench-markingwith otherHPC
transplant centers. The goal was to ensure evidence-based practices
as well as to meet current regulatory standards. The pharmacists’ dil-
igence in procuring and ensuring adequate supply of medications as
well as their timely delivery to patients was crucial in light of recent
drug shortage challenges. Instituting standing orders for electrolyte
replacements, STAT antibiotics, GVHD prophylaxis, and keeping
the majority of medications as floor stock items enabled us to achieve
this goal. In order to administer high-dose chemotherapy safely, twopharmacists independently verify chemotherapy doses against the
standardized regimen listed on the orders.Monographs for keymed-
ications containing information such as drug stability, compatibility,
and special handling were compiled to provide a quick reference and
educational tool for pharmacists.
By participating in daily patient rounds, pharmacists monitored
patients’ clinical status closely, managed complications of high-
dose chemotherapy and adjusted levels of anti-GVHD medications
in a timely manner. To ensure optimal therapeutic dosing with min-
imal toxicity, busulfan pharmacokinetics was implemented under
joint leadership of pharmacists and nurses. In addition, pharmacists
played a major role in educating nurses on high-dose chemotherapy,
immunosuppressive agents and the supportive care for infection,mu-
cositis, nausea and vomiting in allogeneic HPC transplant patients.
In conclusion, pharmacists played a critical role by providing their
expertise in the management of complex drug therapy, monitoring
busulfan pharmacokinetics, educating their peers and thus, contrib-
uting to the success of the program.
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AN EFFECTIVE HEMATOPOIETIC STEM CELL MOBILIZATION ALGORITHM
FOR ADDING PLERIXAFOR TO G-CSF FOR MULTIPLE MYELOMA PA-
TIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION
LaPorte, J.1, Solomon, S.1, Bashey, A.1, Holland, K.1, Morris, L.1,
Sizemore, C.1, Sanacore, M.1, Mihelic, R.1, Leech, M.1, Penland, P.2,
Xang, Z.3 1Northside Hosptial, Atlanta, GA; 2Northside Hospital, At-
lanta, GA; 3Georgia State University, Atlanta, GABackground: Autologous hematopoietic stem cell transplantation
(ASCT) has become an integral part of the treatment for multiple
myeloma (MM). In addition, it is standard practice to collect suffi-
cient stem cells for more than one transplant. Therefore, it is critical
to have an effective mobilization strategy in order to efficiently col-
lect enough CD34+ cells. Administering granulocyte-colony stimu-
lating factor (G-CSF) alone to MM patients can produce sufficient
CD34+ yields in the majority of patients. However, some patients
may require. 4 apheresis days to achieve those yields or fail to col-
lect enough CD34+ cells for ASCT. Plerixafor (P) can increase the
average daily CD34+ yields by 3-fold. Since the majority of patients
can collect withG-CSF alone, an algorithmwas developed in 2009 to
judiciously administer P only to those patients at higher perceived
risk for mobilization failure.
Methods:G-CSF 10mcg/kg/day was administered SC from day 1 to
4.On day 4, a peripheral absoluteCD34+ cell count was drawn. If the
absolute CD34+ count was$ 12 cells/mm3 then apheresis started on
day 5. If the absolute CD34+ count on day 4 was\ 12 cells/mm3 P
240mcg/kg was administered SC the evening prior to apheresis be-
ginning on day 5. During apheresis, if the CD34+ yield was \
1.0x106 CD34+/kg or 50%\the previous collection, Pwas initiated.
The minimum collection yield for all patients was 4.0x106 CD34+/
kg. The maximum number of apheresis days was 5.
Results: From10/09 - 5/11, 68MMpatients weremobilizedwithG-
CSF +/- P. 93%(63/68) of patients achieved minimum collection
yield of 4.0x106CD34+/kg. 99%ofpatients achieved a yield of at least
2.0x106 CD34+/kg. 44% (30/68) of the patients required at least 1
dose of P with the majority requiring it prior to the first apheresis
(83%). Themedian days of apheresis was 2 (1-5). The overall average
yield on the first apheresis day and total yieldwas 4.35x106CD34+/kg
(95%CI+/- 0.64) and 8.71x106CD34+/kg (95%CI+/- 0.93), respec-
tively. 60% (41/68) and 76% (52/68) of patients collected$ 6.0x106
CD34+/kg in# 2 days and# 4 days of apheresis, respectively.
Conclusion: Adding P to G-CSF based upon a day 4 CD34+ count
and collection yields is an effective strategy to mobilize CD34+ cells.
S380 Poster Session IILimitations to the study include a small sample size and an arbitrarily
determined threshold to administer P. A cost-based analysis is cur-
rently being performed to help determine the best day 4 CD34 cutoff
for future studies.
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POTENTIAL COST BENEFIT OF PEGFILGRASTIM COMPARED TO DAILY
FILGRASTIM FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
AT A LARGE TEACHING HOSPITAL
Weber, C.1, Earl, M.1, Kalaycio, M.2 1Cleveland Clinic, Cleveland, OH;
2Cleveland Clinic, Cleveland, OH
The ability of filgrastim (G-CSF) to potentiate hematopoietic recov-
ery following autologous hematopoietic cell transplantation (HCT) is
well-documentedand is currently the standardof care.1 Its use following
allogeneic HCT is less well-delineated, but is often practiced clinically.
Pegfilgrastim, given once every 14 days, is a convenient and potentially
economic alternative to daily G-CSF administration. We retrospec-
tively evaluated the utilization of G-CSF following HCT and its asso-
ciated cost acquisition among 605 total patients transplanted at
a large teaching hospital. Between 1/1/2007 and 8/17/2011, 165 pa-
tients received an allogeneic HCT and an average of 17 doses of G-
CSF (range 2-131) following transplant. Of these patients, 26 received
umbilical cord blood, 113 received bone marrow, and 26 patients re-
ceived peripherally mobilized cells. During the same time period, 440
peripherally mobilized autologous HCT patients received an average
of six daily G-CSF doses (range 1-33). The average wholesale price
(AWP) of G-CSF 480 mcg and pegfilgrastim 6 mg is $477.18 and
$4218.00, respectively. Therefore, pegfilgrastim offers institutional
cost savings if greater than 8 doses of G-CSF are administered. At our
institution during the year 2010, 41 allogeneicHCTand 99 autologous
in-patientHCTwere performed. Substitution ofG-CSFwith one dose
of pegfilgrastim, followed by dailyG-CSFdosing as clinically appropri-
ate, would have decreased our yearly cost expenditures for allogeneic
HCT by approximately $101,000. However, yearly cost expenditures
for autologous HCT would have increased by $179,000. Given that
the use of pegfilgrastim appears to be both safe and efficacious when
compared to daily G-CSF following HCT,2-5 it is reasonable to con-
sider use of this agent, particularly among allogeneic HCT recipients
due to the economic benefit and convenience in administration.
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PBSC MOBILIZATION FOR AUTOLOGOUS TRANSPLANTATION IN MULTI-
PLE MYELOMA AFTER INTENSIVE CHEMOTHERAPY IN PATIENTS WITH
SEVERE RENAL DYSFUNCTION RECEIVING HEMODIALYSIS RESCUE
POST CYCLOPHOSPHAMIDE
Rogosheske, J.R.1, MCClune, B.L.2 1University of Minnesota Medical
Center, Fairview, Minneapolis, MN; 2University of Minnesota, Minne-
apolis, MN
Peripheral blood stem cell (PBSC) mobilization with high dose
(HD) cyclophosphamide (CY) 4gm/m2 and rh-GCSF (10 mg/kg/d)
is routinely used to produce sufficient numbers of stem cells into
the peripheral blood for collection with the added benefit of reduc-
ing tumor load. Guidelines for dosing CY in patients with severe re-
nal dysfunction recommend a dose reduction but could affect
mobilization, disease progression and length of survival. We de-
scribe the outcome of rescue hemodialysis post HD CY on PBSC
collections and CY-related toxicities. Three patients with multiple
myeloma and severe renal insufficiency were given HD CY then un-
derwent 6- hour high flux hemodialysis beginning 14 hours after the
end of the CY infusion. The hemodialysis was timed to remove any
accumulation of CY and its metabolites to prevent unnecessary tox-
icity but also to allow sufficient efficacy and mobilization of stem
cells to occur. The control group (n5 10) had normal renal function
(GFR\70ml/min) and was matched to disease, gender and age. The
mean time to complete stem cell collections (target dose 5 x10^6
CD34 cells/kg) was 24 days (20-26) compared to a control group
of 14 days (10-29). After mobilization the median cell yield was 3.9
x 10^6 CD34 compared to 8.37 x 10^6 CD34 in the control group.
No severe CY toxicities were observed.We conclude that single HD
CY priming in patients with severe renal dysfunction rescued by he-
modialysis effectively produces PBSC but the time to collections
may be delayed and the yield reduced.480
LEVETIRACETAM IS EFFICACIOUS FOR PREVENTION OF BUSULFAN IN-
DUCED SEIZURES
Frame, D.1,Martell, A.1,Markstrom,D.1, Choi, S.2, Couriel,D.2 1Univer-
sity of Michigan, Ann Arbor, MI; 2University of Michigan, Ann Arbor, MI
High-dose busulfan is used in several conditioning regimens in pa-
tientsundergoingallogeneichematopoietic cell transplant (HCT).Bu-
sulfan is known to reduce the seizure threshold, and historically, has
contributed to partial or generalized seizures in up to 10% of patients
without a known history of seizures. Phenytoin has been the primary
agent used in preventing busulfan-induced seizures inmany transplant
programs. However, due to concerns of drug interactions, side effects,
and dosing issues, phenytoin is not an ideal agent in the HCT setting.
For these reasons, the primary prophylaxis at the University of Mich-
igan was changed in April 2009 from phenytoin to levetiracetam 1000
mg twice daily beginning 12 hours prior to Busulfan through 48 hours
after the last busulfan dose for adults and 10mg/kg/dose twice daily
(max1000mg) for children.This retrospective reviewcompared levetir-
acetam (N5 125) to phenytoin (N5 220) for busulfan seizure prophy-
laxis at this single-institution (January 2007- February 2011). Standard
dosing for phenytoin in adult patients was 1000 mg total dose in 3 di-
vided doses beginning the day prior to the initiation of Busulfan, fol-
lowed by 2.5 mg/kg/dose PO twice daily, and continuing for 24 hours
after the last dose of Busulfan; and in children, 5- 7.5mg/kg/dose given
in 3 doses the evening prior to the initiation of Busulfan, followed by
a maintenance dose of 2.5 mg/kg/dose twice daily to be given 24 hours
after the last dose of Busulfan. A free phenytoin level was obtained prior
to the initiation of Busulfan with subsequent daily levels until a thera-
peutic goal level of 1-2 was achieved. Busulfan-based conditioning reg-
imens included: BuCy2, BuCy4, CloBu4, FluBu2, and FluBu4,
respectively. There were two seizures in patients who received phenyt-
oin compared to none in those who received levetiracetam. Based on
thesefindings combinedwith a significant decrease indrug interactions,
levetiracetam is the primary agent for busulfan seizure prophylaxis.
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IMPROVING VACCINATION OF PATIENTS PRE AND POST BONE MARROW
TRANSPLANT
Cooper, J., Krugh, D., Duda, J., Roddy, J., Klisovic, R., Lamprecht, M.,
Beavers-Kirby, J., Hofmeister, C., Dishon-Ritzert, J., Devine, S.OSUCCC
James Cancer Hospital and Solove Research Institute, Columbus, OH
TheOhio State University James Cancer Hospital and Solove Re-
search Institute Blood and Marrow Transplant (BMT) Program de-
veloped a vaccination program (VP) for BMT patients. Several
obstacles were identified that prevented a VP. These included cost,
absence of standard plan of care (POC), and staff awareness of vacci-
nation schedule. An initial POCwas developed in 2008 based on his-
torical data. Twenty-four months after implementation, a quality
assessment (QA) revealed that only 7.6% of allogeneic BMTpatients
had appropriate vaccinations documented at 12 months status post
transplant. A best practice order set was introduced to the outpatient
clinicians who regularly evaluate these patients. Six months after the
best practice order set was introduced, a random sample of 10 patient
charts revealed 100% compliance of the VP.
TheQA captured a snapshot of VP compliance of annual influenza
vaccination and vaccination for allogeneic BMT patients, beginning
12 months status post allogeneic transplant (Tdap, Hib, Hep B,
Pneumococcal, and IPV). For allogeneic BMT patients, only 10%
of the patients were not on immunosuppressive therapy (GvHD
grade 0-2). The QA revealed that allogeneic BMT patients received
annual influenza vaccination; however due to being on immunosup-
pressive therapy (IT) and based on current VP POC, did not receive
recommended vaccination at 12 months.
After a literature review, the revised VP POC was divided into pre-
and post BMT, with distinctions for autologous and allogeneic. Guide-
linesweredeveloped forBMTpatientswith thrombocytopenia, apoten-
tial lapse in the vaccination schedule, patient’s family members, related
BMT donors, and BMT Program staff who may have received live-at-
tenuated vaccination (varicella) during employee health evaluation.
Despite an existing plan of care, there were numerous quality im-
provement opportunities. Evidence based practice should continu-
ously be reviewed and implemented into practice with annual
review of policies, procedure and/or plans of care.
